Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P1BSP3-184342)
'Personalised Health' at ETHZ and University of Basel (PMB-03-17)
Received: 8 April 2021
Accepted: 27 August 2021
First Online: 13 September 2021
: Bacterial strains have been collected in clinical routine diagnostics. The collection of bacterial strains and their analysis for diagnostic assay development do not fall under the Swiss human research act and no ethical approval nor consent to participate from patients was required. The analysis of patient demographic and clinical outcome data was approved by the “Ethikkommission Nordwest- und Zentralschweiz” (EKNZ) (BASEC-Nr. 2016-01899 and 2018-00225) for patients who did not reject the hospitals general research consent. Patients who did reject the hospital’s general consent were excluded from all analyses which include patient demographic and clinical outcome data.All analyses performed in this study were in accordance with the Helsinki Declaration and its later amendments.
: Not applicable.
: VP, FF and RM are employees of the company Mabritec AG, Riehen, Switzerland, which commercializes ribosomal marker-based approaches in MALDI-TOF MS data analyses for identification of microorganisms. FM, MA (Labor Team W AG) and CM (Laborgemeinschaft 1) are employed by private diagnostic laboratories. The remaining authors declare that they have no competing interests.